Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma

Summary To determine the feasibility of liquid biopsy for monitoring of patients with advanced melanoma, cell‐free DNA was extracted from plasma for 25 Stage III/IV patients, most (84.0%) having received previous therapy. DNA concentrations ranged from 0.6 to 390.0 ng/ml (median = 7.8 ng/ml) and wer...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Pigment cell and melanoma research Ročník 31; číslo 1; s. 73 - 81
Hlavní autoři:	Gangadhar, Tara C., Savitch, Samantha L., Yee, Stephanie S., Xu, Wei, Huang, Alexander C., Harmon, Shannon, Lieberman, David B., Soucier, Devon, Fan, Ryan, Black, Taylor A., Morrissette, Jennifer J. D., Salathia, Neeraj, Waters, Jill, Zhang, Shile, Toung, Jonathan, Hummelen, Paul, Fan, Jian‐Bing, Xu, Xiaowei, Amaravadi, Ravi K., Schuchter, Lynn M., Karakousis, Giorgos C., Hwang, Wei‐Ting, Carpenter, Erica L.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Wiley Subscription Services, Inc 01.01.2018
Témata:	Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biopsy Cell-Free Nucleic Acids - blood Cell-Free Nucleic Acids - genetics cell‐free circulating tumor DNA Correlation analysis Deoxyribonucleic acid DNA Feasibility Feasibility Studies Female Gene sequencing High-Throughput Nucleotide Sequencing Humans liquid biopsy Male Melanoma Melanoma - blood Melanoma - diagnosis Melanoma - genetics Middle Aged Monitoring Mutation Patients Pilot Projects precision medicine Skin Neoplasms - blood Skin Neoplasms - diagnosis Skin Neoplasms - genetics Therapy melanoma precision medicine cell-free circulating tumor DNA liquid biopsy
ISSN:	1755-1471, 1755-148X, 1755-148X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Summary To determine the feasibility of liquid biopsy for monitoring of patients with advanced melanoma, cell‐free DNA was extracted from plasma for 25 Stage III/IV patients, most (84.0%) having received previous therapy. DNA concentrations ranged from 0.6 to 390.0 ng/ml (median = 7.8 ng/ml) and were positively correlated with tumor burden as measured by imaging (Spearman rho = 0.5435, p = .0363). Using ultra‐deep sequencing for a 61‐gene panel, one or more mutations were detected in 12 of 25 samples (48.0%), and this proportion did not vary significantly for patients on or off therapy at the time of blood draw (52.9% and 37.5% respectively; p = .673). Sixteen mutations were detected in eight different genes, with the most frequent mutations detected in BRAF, NRAS, and KIT. Allele fractions ranged from 1.1% to 63.2% (median = 29.1%). Among patients with tissue next‐generation sequencing, nine of 11 plasma mutations were also detected in matched tissue, for a concordance of 81.8%.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23
ISSN:	1755-1471 1755-148X 1755-148X
DOI:	10.1111/pcmr.12623